Contagion Editorial Team

FDA approves self-test for HPV, FDA food recalls due to illness outbreaks, FPA approved mpox vaccine available for purchase in the US, and more this month from the FDA.

This week, irrigation water in Utah creates E coli outbreak, FDA issues CRL for HEPLISAV-B 4 dose regimen, living with C diff awareness, and more this week from Contagion.

Hepatitis awareness remains essential to promote prevention and early detection, ensuring access to vaccination and treatment, and improving public health.

Stating low demand, the company is removing their ChAdOx1-S [recombinant] (Vaxzevria) vaccine from the market.

Check out the latest studies, management strategies, patient advocacy, and other important news involving this condition.

Public health alert over ground beef, FDA approves antibiotics for female adults with uncomplicated UTI, The NYC Department of Health and Mental Hygiene reports a record amount of Leptospirosis cases, and more this week from Contagion.

Here is an update on the latest research and clinical management.

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

This week, the FDA-approved antiretroviral lenacapavir as it showed treatment benefits; Oral Vancomycin Prophylaxis was explored for preventing C difficile in stem cell transplant recipients; Research into the after-effects of SARS-CoV-2 (PASC) uncovers biomarkers for post-infection sequelae; Chronic hepatitis B worsens COVID-19 outcomes, and cabotegravir ultra-long-acting (CABULA) has shown positive results.

This week, why measles and vibrio vulnificus infections are seeing outbreaks and increases in incidence rates; a medical association recommends fecal microbiota-based therapies for recurrent or severe C difficile; and an antiviral reduced a median time-to-symptom resolution.

The Centers for Disease Control and Prevention (CDC) considers changing its previous guidance.

This week a new vaccine for HIV is under development, a COVID-19 vaccine receives WHO emergency approval, and several local US health departments receive funding to combat antimicrobial resistance.

This week: Insights into the comparative analysis of COVID and non-COVID pneumonia; how myopathy, with metabolic disturbances and amyloid deposits, is discovered in persons with Long COVID who experience post-exertional malaise; and the Pfizer COVID-19 vaccine is shown to be effective in children and adolescents.

This week's news includes emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus; how the development of antimicrobial stewardship programs can be an effective strategy for beginning to reduce this critical timing for patients in ICUs; a look at another antibiotic being studied for a healthcare-associated infection; and an investigational vaccine against the Nipah virus begins.

The week's news included the differences in public attitudes towards influenza and COVID-19 vaccines, sex-based differences in direct-acting antivirals, a request for an emergency use authorization for a monoclonal antibody for COVID-19 prevention in the immunocompromised, and our final episode of our RSV Roundtable series, which has clinicians weighing in on the importance of counseling patients on the immunizations now and their significance for the future.

Recall affects several raw bulk products sent to restaurants and institutional users, and are marked either angus ground beef patties, ground beef patties, or ground beef.

This year saw the approval of new therapies as well as the continued evolution of time-to-treat infections and updated guidelines.

In 2023, there were numerous developments in hepatitis C including the Biden Administration's new budget that put aside several billion dollars towards establishing a hepatitis C (HCV) program; the Cherokee Nation's Hepatitis C elimination program which has worked to increase screening and get people into the continuum of care; and how one clinician is bringing HCV care to the streets through her mobile clinics. Check out these stories and more from this year.

The company, RNAimmune, got the ok from the FDA for its vaccine, RV-1770.

The Manischewitz corporation issued the voluntary effort on some limited units of their dark chocolate coins and should be considered for people who have a milk allergy or are severely sensitive to it.

With the holiday upon us, here are some considerations for dinner prep as well as some recent FDA food recalls.

ACON Laboratories’ Flowflex COVID-19 Antigen Home Test completed the premarket review pathway and is the first test indicated for use in children under 18.

This week read about virus testing, the dosing of one of the COVID-19 vaccines in the pediatric population, HAI grades in hospitals, and live biotherapeutic products in preventing recurrent CDI in older adults with comorbidities.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

The companies' initial focus will be around Assembly’s established areas of development including hepatitis B and D, as well as herpesviruses.

This antibiotic is the only liquid oral suspension approved in the US.

The formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) is a once-daily treatment for children living with HIV and meant to reduce pill burden.

A congressional subcommittee aims at reducing HIV-related budget items by over half a billion dollars.

A new study finds antimicrobial resistance (AMR) evolves rapidly in patients colonized by diverse P aeruginosa populations due to selection for preexisting resistant strains, demonstrating a clear link between within-host diversity and resistance.

We have developed our new Clinical Corner column and have other ways providers can get involved with Contagion.